ESTRO 2024 - Abstract Book

S1385

Clinical - Head & neck

ESTRO 2024

The medical records of 625 patients were studied. There were 187 (29.9 %) patients with LVI and 438 (70.1 %) patients without LVI. The median follow-up for patients with LVI and without LVI was 22.1 months and 31.9 months respectively. The median duration of LRC had not reached in either cohort till the time of analysis (Figure 1). The 3- year LRC rate in patients with LVI and without LVI was 74.9 % and 64.6 % respectively (p = 0.019). The 5-years LRC rate in patients with LVI and without LVI was 64.9 % and 61.6 % respectively (p = 0.106). The median duration of OS in patients with LVI and without LVI was 33.6 months and 83.5 months respectively (p = <0.001) (Figure 2). The 3- year OS rate in patients with LVI and without LVI was 49.8 % and 67.1% respectively (p <0.001). The 5-years OS rate in patients with LVI and without LVI was 44.1 % and 58.5 % respectively (p <0.001). Univariate and multivariate analysis identified LVI to a significant factor affecting OS (Table 1).

Table 1: Univariate and multivariate analysis for Overall survival

Univariate Analysis

Multivariate Analysis

HR (95%CI);

p

HR (95%CI);

p

Variable

Category

value

value

0.865 (0.812-0.940); p value = 0.032 1.209 (0.772 – 3.330): p value = 0.287 0.810 (0.533 – 2.792): p value = 0.533 0.622 (0.309-0.887): p value = 0.018

0.901 (0.825-1.201); p value = 0.2662

Age

Continuous

Tobacco

Consumption

Alcohol

Consumption

0.421 (0.302-0.899): p value = 0.009

Gender

Female

Grade

WD

Reference